Breaking the mould: challenging the status quo of clinical trial response definitions for invasive fungal diseases—a debate
Journal of Antimicrobial Chemotherapy · 01.08.2024 · 79 (8) · 1786-1793
DOI: 10.1093/jac/dkae158 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 01.08.2024. Verfasst von Johan Maertens und 5 weiteren Autor:innen. Beteiligte Einrichtung: University Hospitals Leuven, Department of Haematology and ECMM Excellence Center of Medical Mycology, Campus Gasthuisberg Leuven, Belgium. Hauptthemen laut MEDLINE: Invasive Fungal Infections, Clinical Trials as Topic, Antifungal Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Shionogi B.V., London, UK, F2G Ltd, Manchester, UK.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University Hospitals Leuven, Department of Haematology and ECMM Excellence Center of Medical Mycology, Campus Gasthuisberg Leuven, Belgium.
- Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
- Division of Infectious Diseases, ECMM Excellence Center of Medical Mycology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
- Division of Infectious Diseases, and Departments of Internal Medicine and Medical Microbiology and Immunology, University of California-Davis, Sacramento, CA, USA.
- Mycology Reference Centre Manchester, ECMM Excellence Center of Medical Mycology, Manchester University NHS Foundation Trust, Manchester, UK.
- Christian-Doppler Laboratory for Invasive Fungal Infections, Institute of Hygiene and Medical Microbiology, ECMM Excellence Center of Medical Mycology, Medical University of Innsbruck, Innsbruck, Austria.
ORCID-Profile: Monica Slavin, George R Thompson
Förderung
- Shionogi B.V., London, UK
- F2G Ltd, Manchester, UK
Zitieren
APA
Maertens, J., Slavin, M., Hoenigl, M., Thompson, G. R., Richardson, M., & Lass-Flörl, C. (2024). Breaking the mould: challenging the status quo of clinical trial response definitions for invasive fungal diseases—a debate. Journal of Antimicrobial Chemotherapy, 79(8), 1786-1793. https://doi.org/10.1093/jac/dkae158
Vancouver
Maertens J, Slavin M, Hoenigl M, Thompson GR, Richardson M, Lass-Flörl C. Breaking the mould: challenging the status quo of clinical trial response definitions for invasive fungal diseases—a debate. Journal of Antimicrobial Chemotherapy. 2024;79(8):1786-1793. doi:10.1093/jac/dkae158
BibTeX
@article{Maertens2024,
author = {Maertens, Johan and Slavin, Monica and Hoenigl, Martin and Thompson, George R and Richardson, Malcolm and Lass-Flörl, Cornelia},
title = {Breaking the mould: challenging the status quo of clinical trial response definitions for invasive fungal diseases—a debate},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
volume = {79},
number = {8},
pages = {1786--1793},
doi = {10.1093/jac/dkae158}
}
EUVIMED